The U.S. Food and Drug Administration (FDA) approved a supplemental application for Cosentyx (secukinumab) on March 12, 2026. This approval, designated BLA 125504 S-91, relates to the efficacy of the drug, with Novartis Pharmaceuticals Corporation as the sponsor.
Background
Cosentyx, also known by its generic name secukinumab, is a biologic medication. This supplemental approval pertains specifically to its efficacy, as indicated by the FDA's classification of the application. The sponsor for Cosentyx is Novartis Pharmaceuticals Corporation.
What this means
A supplemental application for efficacy, such as this approval for Cosentyx (secukinumab), typically indicates that the sponsor, Novartis Pharmaceuticals Corporation, has submitted new data supporting the drug's effectiveness. This could relate to an existing approved indication, potentially demonstrating improved outcomes, or it might pave the way for a future label expansion if further specific data were to be submitted and approved. For healthcare providers, this type of approval reinforces the drug's therapeutic value and ensures that its efficacy profile is continually updated and validated by regulatory bodies. Researchers may find this significant as it points to ongoing clinical development and data generation for secukinumab. Patient advocates can view this as a commitment to ensuring medications remain effective and well-understood for their intended uses.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) on March 12, 2026. The details are publicly available on the accessdata.fda.gov website, specifically referencing BLA 125504 S-91, under the sponsorship of Novartis Pharmaceuticals Corporation.